Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
FULC
Stock Latest News
Company Announcements
Fulcrum’s Pociredir Trial Completion Adds a New Catalyst to the Sickle Cell Investment Story
23h ago
FULC
Premium
The Fly
JPMorgan large/SMid cap biotech analysts hold analyst/industry conference call
3d ago
AGIO
FULC
Premium
Ratings
De-Risked Efficacy and Clean Safety for Pociredir in Sickle Cell Disease Position FULC for Re-Rating Ahead of 1Q26 Data
18d ago
FULC
Premium
Company Announcements
Fulcrum Therapeutics updates strategy on lead sickle cell therapy
1M ago
8K
FULC
Premium
The Fly
Fulcrum Therapeutics initiated with an Overweight at JPMorgan
1M ago
FULC
Premium
The Fly
Fulcrum Therapeutics price target raised to $18 from $14 at Truist
2M ago
FULC
Premium
Company Announcements
Fulcrum Therapeutics Announces $175 Million Public Offering
2M ago
8K
FULC
Premium
The Fly
Fulcrum Therapeutics 11.85M share Secondary priced at $13.50
2M ago
FULC
Premium
The Fly
Fulcrum Therapeutics price target raised to $7 from $6 at BofA
2M ago
FULC
Premium
Ratings
Cautious Outlook for Fulcrum Therapeutics Amidst PIONEER Study Challenges and Market Uncertainties
2M ago
FULC
Premium
The Fly
Fulcrum Therapeutics announces $150M offering of common stock
2M ago
FULC
Premium
The Fly
Fulcrum Therapeutics price target raised to $25 from $20 at Stifel
2M ago
FULC
Premium
The Fly
Fulcrum Therapeutics price target raised to $24 from $15 at Cantor Fitzgerald
2M ago
FULC
Premium
The Fly
Fulcrum Therapeutics price target raised to $10 from $7 at RBC Capital
2M ago
FULC
Premium
Company Announcements
Fulcrum Therapeutics Reports Positive Phase 1b Trial Results
2M ago
8K
FULC
Premium
The Fly
Fulcrum Therapeutics price target raised to $23 from $16 at Piper Sandler
2M ago
FULC
Premium
The Fly
Fulcrum Therapeutics price target raised to $25 from $18 at H.C. Wainwright
2M ago
FULC
Premium
The Fly
Fulcrum announces results from 20 mg dose cohort of Phase 1b PIONEER trial
2M ago
FULC
Premium
The Fly
Fulcrum Therapeutics initiated with a Buy at Truist
3M ago
FULC
Premium
Ratings
Buy Rating for Fulcrum Therapeutics Driven by Promising PIONEER Study Results and Market Potential of Pociredir
3M ago
FULC
Premium
Ratings
Fulcrum Therapeutics: Promising Sickle Cell Treatment with Pociredir Outshines Competitors
3M ago
FULC
Premium
The Fly
Fulcrum’s pociredir shows promising early efficacy vs. mitapivat, says Leerink
3M ago
AGIO
FULC
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
